The Food and Drug Administration published draft guidance on October 27 describing how individualized gene editing products could be licensed: multiple patient specific variants inside a single Biologics License Application, organized around what the agency calls an Individualized Feature Space, a predefined description of how far the product may vary from one patient to another while staying inside the same licence.
Under the draft, a new variant that falls within the established feature space, and that is predicted to have adequate safety and activity from clinical or laboratory data, would be handled as a manufacturing change rather than as a new product. The Regulatory Affairs Professionals Society reported that the feature space should describe which types of targeting sequences are allowable, aimed at a defined class of pathogenic variants in a specified gene and producing the same editing outcome. CBER official Andrew Byrnes said the current one licence per patient approach is infeasible and unnecessary.
The draft builds on a sequence of earlier documents: January 2024 draft guidance on gene therapy products incorporating genome editing, the February 2026 draft plausible mechanism framework for individualized therapies in diseases too rare for randomized trials, an April 2026 draft on safety assessment using next generation sequencing, and June 2026 draft guidance on leveraging prior knowledge across genome editing programs. Rare disease advocates welcomed the step. Paul Scribner of the PKD Foundation, speaking at a rare disease event on Tuesday, called it putting a flag in the ground, STAT reported.
The limits matter as much as the opening. The draft is nonbinding, marked not for implementation, covers monogenic diseases with known pathogenic variants, and does not itself design the trials sponsors must run. Comments are due November 27, 2026, under docket FDA-2026-D-11783.